title: Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?
authors.forename: Francesco
authors.initials: F
authors.lastname: Pignatti
authors.forename: Rob
authors.initials: R
authors.lastname: Hemmings
authors.forename: Bertil
authors.initials: B
authors.lastname: Jonsson
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015982:Bias; D017326:Clinical Trials, Phase III as Topic / Q000379:methods* / Q000639:trends; D015986:Confounding Factors, Epidemiologic; D018450:Disease Progression; D018572:Disease-Free Survival; D017277:Drug Approval; D023381:Endpoint Determination / Q000379:methods* / Q000639:trends; D006801:Humans; D008485:Medical Audit / Q000379:methods / Q000639:trends; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D011859:Radiography; D016032:Randomized Controlled Trials as Topic / Q000379:methods* / Q000639:trends; D012107:Research Design / Q000592:standards / Q000639:trends; D016037:Single-Blind Method; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents